D
Douglas S. Reintgen
Researcher at American Society of Clinical Oncology
Publications - 9
Citations - 5378
Douglas S. Reintgen is an academic researcher from American Society of Clinical Oncology. The author has contributed to research in topics: Cancer & Melanoma. The author has an hindex of 5, co-authored 9 publications receiving 5243 citations. Previous affiliations of Douglas S. Reintgen include Royal Adelaide Hospital & University of Texas Health Science Center at Houston.
Papers
More filters
Journal ArticleDOI
Final Version of the American Joint Committee on Cancer Staging System for Cutaneous Melanoma
Charles M. Balch,Antonio C. Buzaid,Seng Jaw Soong,Michael B. Atkins,Natale Cascinelli,Daniel G. Coit,Irvin D. Fleming,Jeffrey E. Gershenwald,Alan Houghton,John M. Kirkwood,Kelly M. McMasters,Martin F. Mihm,Donald L. Morton,Douglas S. Reintgen,M. I. Ross,Arthur J. Sober,John A. Thompson,John F. Thompson +17 more
TL;DR: This revision of the staging system for cutaneous melanoma will become official with publication of the sixth edition of the AJCC Cancer Staging Manual in the year 2002.
Journal ArticleDOI
Prognostic Factors Analysis of 17,600 Melanoma Patients: Validation of the American Joint Committee on Cancer Melanoma Staging System
Charles M. Balch,Seng Jaw Soong,Jeffrey E. Gershenwald,John F. Thompson,Douglas S. Reintgen,Natale Cascinelli,Marshall M. Urist,Kelly M. McMasters,M. I. Ross,John M. Kirkwood,Michael B. Atkins,John A. Thompson,Daniel G. Coit,David R. Byrd,Renee A. Desmond,Yuting Zhang,Ping-Yu Liu,Gary H. Lyman,Aberto Morabito +18 more
TL;DR: The proposed tumor-node-metastases categories and stage groupings for cutaneous melanoma patients were validated and incorporated into the AJCC melanoma staging as described in the companion publication.
Journal Article
Selective lymphadenectomy: Emerging role for lymphatic mapping and sentinel node biopsy in the management of early stage melanoma
TL;DR: The present series substantiates the results of the original study and proposes an international multicenter trial to further confirm the accuracy and universal feasibility of the intraoperative lymphatic mapping and sentinel node biopsy technique.
Journal ArticleDOI
The Impact on Morbidity and Length of Stay of Early Versus Delayed Complete Lymphadenectomy in Melanoma: Results of the Multicenter Selective Lymphadenectomy Trial (I)
Mark B. Faries,John F. Thompson,Alistair J. Cochran,Robert Elashoff,Edwin C. Glass,Nicola Mozzillo,Omgo E. Nieweg,Daniel F. Roses,Harold J. Hoekstra,Constantine P. Karakousis,Douglas S. Reintgen,Brendon J. Coventry,He-Jing Wang,Donald L. Morton +13 more
TL;DR: Immediate nodal treatment provides critical prognostic information and a likely therapeutic effect for those patients with nodal involvement and data show that early CLND is also less likely to result in lymphedema.
Journal Article
Lymphatic mapping and sentinel node biopsy in patients with malignant melanoma.
TL;DR: The survival benefit recently reported in patients with melanoma metastatic to regional nodes prospectively randomized to receive high dose Interferon alfa-2b signals that the surgeons should aggressively examine patients for the presence of occult regional melan cancer metastases.